Log in
Sign up
Donate
Find a person or team
Donate once to MovemberDonate monthly to Movember
Support UsAbout UsMen's HealthStories
"Movember news: Movember awards $500,000 to cancer research. Winner of the 2023 Movember-PCF Challenge Awards announced"
"This exciting project is aiming to transform the treatment approach."Image by: Movember
"Movember news: Movember awards $500,000 to cancer research. Winner of the 2023 Movember-PCF Challenge Awards announced"
7 December 2023

Announcing the 2023 Movember-PCF Challenge Award winner

Movember
2 minutes read time

Movember is delighted to announce the winner of the 2023 Movember-PCF Challenge Awards, along with our partners at the Prostate Cancer Foundation (PCF).

Movember is contributing $500,000 towards this annual award which is granted to teams at some of the world’s leading cancer research institutions to support pioneering research in the field of prostate cancer.

The team who received funding this year is led by Dr. Mary-Ellen Taplin at the Dana Farber Cancer Institute in Boston.

A lot of men diagnosed with a high-risk prostate cancer that is thought to be localized to the prostate may have ‘hidden’ disease that has spread to other parts of the body (metastatic prostate cancer).

While studies have shown that more intensive treatment for metastatic prostate cancer can improve outcomes, we don’t know if the same intensive treatment on all or some groups of men with ‘hidden’ metastatic prostate cancer would also lead to improved outcomes.

Through the Movember-PCF Challenge Award, Dr. Taplin and her team will harness the use of artificial intelligence to look for unique biological signatures that can identify men with ‘hidden’ metastatic prostate cancer, who are at the greatest risk of their disease returning after initial treatment.

They will also test if these unique biological signatures can accurately pinpoint a specific group of men who would benefit from intensive treatment. This approach would also spare other men from unnecessary therapy and its side effects if their cancer is not likely to progress.

Dr. Sarah Hsiao, Director of Biomedical Research and Impact at Movember, said: “This exciting project is aiming to transform the treatment approach for men with high-risk localized prostate cancer, so that fewer men will go on to develop advanced disease. Movember’s mission is to reduce the number of men whose disease progresses to lethal prostate cancer, so we are proud to be supporting Dr. Taplin’s research in collaboration with our partner, the Prostate Cancer Foundation.”